CarboplatinRecent, repeatedPhase 4 trial recordedEvidence- NCT07777822 · Revolution Medicines, Inc. · Phase 3 · live · background · “pemetrexed + cisplatin /carboplatin” · registered Aug 2026
- NCT07625644 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin” · registered May 2026
- NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Carboplatin” · registered Mar 2026
- NCT07486817 · Boehringer Ingelheim · Phase 2 · live · background · “Carboplatin” · registered Mar 2026
- NCT07229599 · Minghui Pharmaceutical · Phase 2 · live · background · “Carboplatin” · registered Nov 2025
| Eli Lilly and Company16% of its industry studies | 1524 studies | 1625 studies | comparator 9 · background 52 |
pembrolizumabRecent, repeatedEvidence- NCT07777822 · Revolution Medicines, Inc. · Phase 3 · live · background · “pembrolizumab” · registered Aug 2026
- NCT07223047 · Bristol-Myers Squibb · Phase 2 · live · background · “Pembrolizumab” · registered Oct 2025
- NCT07222566 · Pfizer · Phase 3 · live · comparator · “Pembrolizumab” · registered Oct 2025
- NCT07162883 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Keytruda®” · registered Aug 2025
- NCT07063745 · Bristol-Myers Squibb · Phase 3 · live · background · “Pembrolizumab” · registered Jul 2025
| Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015) | 1419 studies | 1419 studies | comparator 8 · background 16 |
PemetrexedRecent, repeatedEvidence- NCT07777822 · Revolution Medicines, Inc. · Phase 3 · live · background · “pemetrexed + cisplatin /carboplatin” · registered Aug 2026
- NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Pemetrexed” · registered Mar 2026
- NCT07486817 · Boehringer Ingelheim · Phase 2 · live · background · “Pemetrexed” · registered Mar 2026
- NCT07154368 · Guangzhou JOYO Pharma Co., Ltd · Phase 3 · live · background · “Pemetrexed injection” · registered Aug 2025
- NCT07100080 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Pemetrexed” · registered Jul 2025
| Eli Lilly and Company67% of its industry studiesUS: off-patent, 4 generics marketedEU: off-patent, 3 generics authorized | 1018 studies | 1119 studies | comparator 12 · background 29 |
DocetaxelRecent, repeatedEvidence- NCT06881784 · Revolution Medicines, Inc. · Phase 3 · live · comparator · “docetaxel” · registered Mar 2025
- NCT06780098 · Merck & Co., Inc · Phase 2 · live · comparator · “Docetaxel” · registered Jan 2025
- NCT06635824 · Genmab · Phase 3 · live · comparator · “Docetaxel” · registered Oct 2024
- NCT06228326 · Krystal Biotech, Inc. · Phase 2 · live · background · “Docetaxel” · registered Jan 2024
- NCT06012435 · Pfizer · Phase 3 · live · comparator · “docetaxel” · registered Aug 2023
| Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized | 88 studies | 88 studies | comparator 11 · background 10 |
CisplatinRecent, repeatedEvidence- NCT07777822 · Revolution Medicines, Inc. · Phase 3 · live · background · “pemetrexed + cisplatin /carboplatin” · registered Aug 2026
- NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Cisplatin” · registered Mar 2026
- NCT07486817 · Boehringer Ingelheim · Phase 2 · live · background · “Cisplatin” · registered Mar 2026
- NCT07100080 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Cisplatin” · registered Jul 2025
- NCT07063745 · Bristol-Myers Squibb · Phase 3 · live · background · “Cisplatin” · registered Jul 2025
| Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed | 714 studies | 815 studies | comparator 11 · background 23 |
PaclitaxelRecent, repeatedEvidence- NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Paclitaxel” · registered Mar 2026
- NCT07063745 · Bristol-Myers Squibb · Phase 3 · live · background · “Paclitaxel” · registered Jul 2025
- NCT06788912 · Merck & Co., Inc · Phase 2 · live · comparator · “Paclitaxel” · registered Jan 2025
- NCT06731907 · Merck & Co., Inc · Phase 2 · live · comparator · “Paclitaxel” · registered Dec 2024
- NCT06712316 · BioNTech SE · Phase 3 · live · background · “Paclitaxel” · registered Nov 2024
| Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed | 48 studies | 711 studies | comparator 6 · background 30 |
osimertinibRecent, repeatedEvidence- NCT07285148 · Beijing Pearl Biotechnology Limited Liability Company · Phase 2 · live · comparator · “ANS014004 + Osimertinib” · registered Nov 2025
- NCT06618287 · Bristol-Myers Squibb · Phase 2 · live · background · “Osimertinib” · registered Sep 2024
- NCT06574347 · Avistone Biotechnology Co., Ltd. · Phase 2 · live · comparator · “Osimertinib” · registered Aug 2024
- NCT05498389 · Shanghai EpimAb Biotherapeutics Co., Ltd. · Phase 2 · live · background · “Osimertinib” · registered Jun 2022
- NCT03989115 · Revolution Medicines, Inc. · Phase 2 · background · “Drug: Osimertinib” · registered Jun 2019
| AstraZeneca93% of its industry studiesUS: AstraZeneca (FDA 2015)EU: AstraZeneca (EMA 2016) | 44 studies | 44 studies | background 4 · comparator 2 |
GemcitabineRecent, repeatedEvidence- NCT07492680 · Bristol-Myers Squibb · Phase 2 · live · background · “Gemcitabine” · registered Mar 2026
- NCT07223047 · Bristol-Myers Squibb · Phase 2 · live · background · “Gemcitabine” · registered Oct 2025
- NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Gemcitabine + Nab-paclitaxel” · registered May 2025
- NCT06788912 · Merck & Co., Inc · Phase 2 · live · comparator · “Gemcitabine” · registered Jan 2025
- NCT06312137 · Merck & Co., Inc · Phase 3 · live · background · “Gemcitabine” · registered Mar 2024
| Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed | 35 studies | 57 studies | comparator 4 · background 14 |
Albumin-Bound PaclitaxelRecent, repeatedEvidence- NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Gemcitabine + Nab-paclitaxel” · registered May 2025
- NCT06731907 · Merck & Co., Inc · Phase 2 · live · comparator · “Nab-paclitaxel” · registered Dec 2024
- NCT05633667 · Gilead Sciences · Phase 2 · live · comparator · “Nab-paclitaxel” · registered Nov 2022
- NCT05014815 · BeOne Medicines · Phase 2 · background · “Nab paclitaxel” · registered Aug 2021
- NCT04222972 · Hoffmann-La Roche · Phase 3 · comparator · “Nab-Paclitaxel” · registered Jan 2020
| Bristol-Myers Squibb43% of its industry studiesEU: Bristol-Myers Squibb (EMA 2008) | 33 studies | 55 studies | background 5 · comparator 3 |
EtoposideRecent, repeatedEvidence- NCT07625644 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin” · registered May 2026
- NCT06712355 · BioNTech SE · Phase 3 · live · background · “Etoposide” · registered Nov 2024
- NCT05652686 · Phanes Therapeutics · Phase 2 · live · background · “Carboplatin + Etoposide” · registered Dec 2022
- NCT04380636 · Merck & Co., Inc · Phase 3 · live · background · “Etoposide” · registered May 2020
- NCT03699956 · EpicentRx, Inc. · Phase 3 · background · “Cisplatin/carboplatin plus etoposide” · registered Oct 2018
| Hoffmann-La Roche14% of its industry studiesUS: off-patent, 5 generics marketed | 33 studies | 44 studies | background 6 · comparator 1 |
CetuximabRecent, repeatedEvidence- NCT07286149 · Merck & Co., Inc · Phase 2 · live · background · “Cetuximab” · registered Nov 2025
- NCT07223047 · Bristol-Myers Squibb · Phase 2 · live · background · “Cetuximab” · registered Oct 2025
- NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Cetuximab” · registered May 2025
| Eli Lilly and Company33% of its industry studiesUS: Eli Lilly and Company (FDA 2004)EU: Merck KGaA, Darmstadt, Germany (EMA 2004) | 33 studies | 33 studies | background 3 |
Antineoplastic AgentsRecent, repeatedEvidence- NCT07476287 · Pfizer · Phase 2 · live · background · “Chemotherapy” · registered Mar 2026
- NCT06228326 · Krystal Biotech, Inc. · Phase 2 · live · background · “Chemotherapy” · registered Jan 2024
- NCT04495153 · Candel Therapeutics, Inc. · Phase 2 · live · background · “Chemotherapy” · registered Jul 2020
- NCT02873416 · ningbo cancer hospital · Phase 2 · background · “Chemotherapy” · registered Aug 2016
- NCT02862587 · Shanghai International Medical Center · Phase 2 · background · “Chemotherapy” · registered Aug 2016
| — | 22 studies | 33 studies | background 8 |
IrinotecanRecent, repeatedEvidence- NCT05652686 · Phanes Therapeutics · Phase 2 · live · background · “Irinotecan (drug)” · registered Dec 2022
- NCT05592626 · Marengo Therapeutics, Inc. · Phase 2 · live · background · “Irinotecan (Camptosar)” · registered Oct 2022
- NCT03678883 · Actuate Therapeutics Inc. · Phase 2 · live · background · “Irinotecan” · registered Sep 2018
- NCT02489903 · EpicentRx, Inc. · Phase 2 · comparator · “Irinotecan” · registered Jun 2015
| Pfizer17% of its industry studiesUS: off-patent, 7 generics marketedEU: Les Laboratoires des Médicaments Stériles (EMA 2016) | 22 studies | 33 studies | background 3 · comparator 1 |
atezolizumabRecent, repeatedEvidence- NCT07625644 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin” · registered May 2026
- NCT06712355 · BioNTech SE · Phase 3 · live · comparator · “Atezolizumab” · registered Nov 2024
- NCT04471727 · Merck & Co., Inc · Phase 2 · live · background · “Atezolizumab” · registered Jul 2020
| Hoffmann-La Roche91% of its industry studiesUS: Hoffmann-La Roche (FDA 2016)EU: Hoffmann-La Roche (EMA 2017) | 22 studies | 33 studies | background 2 · comparator 1 |
lurbinectedinRecent, repeatedEvidence- NCT07625644 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin” · registered May 2026
- NCT05652686 · Phanes Therapeutics · Phase 2 · live · background · “Lurbinectedin” · registered Dec 2022
| PharmaMar74% of its industry studiesUS: JAZZ (FDA 2020)EU: Pharma Mar S.A. (EMA 2026) | 22 studies | 22 studies | background 2 |